CYTOPHAGE Aktie

 

WINNIPEG, November 28, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that it has now closed the remainder  of its previously announced non-brokered private placement (the “Offering”). The full details of the Offering were announced in a press release dated October 17, 2025.  In connection with the closing, the Company raised an additional $198,000 of gross proceeds by issuing a total of 990,000 Units to investors, to bring the total gross proceeds to $1,200,000.   Each Unit, priced at $0.20, consists of one (1) common share of the Company (a “Share”) and one half (1/2) of a common share purchase warrant (a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one (1) additional Share ( a “Warrant Share”) at a price of C$0.40 per Warrant Share, for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the Warrants if the volume weighted average trading pr...

WINNIPEG, November 12, 2025 — TheNewswire – Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today reported that it has closed the first-tranche of its previously announced non-brokered private placement (the “Offering”). The full details of the Offering were announced in a press release dated October 17, 2025.  In connection with the first--tranche closing, the Company raised $1.002M of gross proceeds by issuing a total of 5,010,000 Units to investors. The Company plans to close a secondary tranche of the Offering on or about November 17, 2025. As stated in its earlier press release, the Company may also increase the size of the Offering by issuing up to an additional 3,000,000 Units for additional gross proceeds of up to $600,000 to accommodate additional demand from investors. Each Unit consists of one (1) common share of the Company (a “Share”) and one half (1/2) of a common share purchase warrant (a “Warrant”). Each whole Warrant entitles the ...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES WINNIPEG – TheNewswire - November 5, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today reported that it will proceed to close its previously announced non-brokered unit private placement (the “Offering”). The full details of the Offering were announced in a press release dated October 17, 2025. The Company has received orders and indications for approximately 6,000,000 units, representing approximately $1.2 million of proceeds. The Company anticipates that it will close the Offering on November 10, 2025, with a secondary tranche as necessary on November 17, 2025. As stated in its earlier press release, the Company may increase the size of the Offering by up to $600,000 to accommodate additional demand from investors who continue to evaluate the Company.   About Cytophage  Cytophage Technologies (TSXV:CYTO / FSE: 70G) is a pioneering biotechnology company dedicated to bacter...

Winnipeg, den 17. Oktober 2025 / IRW-Press / Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G), ein Biotechnologieunternehmen, das innovative Bakteriophagenlösungen für......

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES WINNIPEG – TheNewswire - October 17, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced a non-brokered private placement of up to 6,000,000 units (each, a “Unit”) at C$0.20 per Unit, for gross proceeds of up to $1,200,000 (the “Offering”).  The Company reserves the right to increase the size of the Offering by up to an additional $600,000 through the sale of up to 3,000,000 additional Units. Each Unit consists of one (1) common share of the Company (a “Share”) and one half (1/2) of a common share purchase warrant (a “Warrant”). Each whole Warrant entitles the holder thereof to purchase one (1) additional Share ( a “Warrant Share”) at a price of C$0.40 per Warrant Share, for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the Warrants if the volume weighted average trading price of its Common Shares on the TSX Ven...

WINNIPEG, Manitoba--(BUSINESS WIRE)--The Bioscience Association Manitoba (BAM) is pleased to announce the appointment of new members to its Board of Directors following the organization's Annual General Meeting, held on October 16, 2025. The AGM brought together members, partners, and stakeholders to celebrate achievements from the past year and to look ahead at new opportunities for Manitoba's bioscience sector. As part of the meeting, members elected new directors to the BAM board. The BAM Board of Directors provides strategic direction and oversight, ensuring the association continues to support and advocate for Manitoba's bioscience community. This year, BAM is proud to welcome the following new directors: - Dvorah Richler, Emergent BioSolutions Inc. - Krista Coventry, Source Nutraceutical Inc. - Tasia Lightly, Cytophage Technologies Ltd. “We're thrilled to welcome these new directors, who bring a wide range of expertise and insights from across the bioscience sector,” said Andrea Ladouceur, P...

Winnipeg, den 16. Oktober 2025 - Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G), ein Biotechnologieunternehmen, das innovative Bakteriophagenlösungen für die Gesundheit......

  Winnipeg, Manitoba – October 16, 2025 – TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”), a biotechnology company developing innovative bacteriophage solutions for animal and human health, is pleased to announce that W.L.T. Distributors Inc. (WLT), a Manitoba-based agricultural supply company, has agreed to distribute OvaPhage across Canada. OvaPhage is a bacteriophage product for eggs designed to reduce Salmonella load on egg shells, improving food safety and decreasing reliance on harsh chemical cleaning solutions.     This announcement follows Cytophage's recent receipt of Health Canada's Letter of No Objection (LONO) for the sale of OvaPhage. The LONO represents a key regulatory milestone for Cytophage and marks one of the first commercial bacteriophage products of its kind that will be available for sale in Canada.   “Cytophage is excited to have WLT Distributors on board to sell OvaPhage in Canada,” said Dr. Steven Theriault, Chief Executive Officer of...

Winnipeg, den 29. September 2025 - Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G) gab seine Teilnahme an der kanadischen Bioproduktionsmission bekannt, die vom 21. bis......

WINNIPEG – TheNewswire - September 29, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) announced its participation in the Canadian biomanufacturing mission held in Lyon and Paris, France from September 21-25, 2025 under the Canadian International Innovation Program (CIIP). This government-led initiative, organized by Global Affairs Canada and the National Research Council of Canada, brought together leading Canadian companies to explore co-innovation opportunities within the French bioeconomy. “We engaged with prospective European partners on this mission to help advance the commercialization of our bacteriophage products globally,” said Dr. Steven Theriault, CEO of Cytophage. “We were honoured to represent Canadian innovation alongside our esteemed industry peers, and grateful for the federal government's support for this mission. We extend our sincere thanks to the Trade Commissioner Service | Service des délégués commerciaux of Canada and ...

Winnipeg, den 23. September 2025 Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G) meldete heute positive Ergebnisse seiner europäischen Folgestudie zu AviPhage, dem......

    WINNIPEG, September 23, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced positive results from its follow-up European pilot study of AviPhage, the Company's proprietary poultry-based bacteriophage (phage) product for broiler chickens. These results reinforce the efficacy of AviPhage as a strong contender for antibiotic replacement in poultry farms, provide valuable new data that builds upon the initial pilot study findings, and mark another milestone in advancing the product toward regulatory approval and commercial launch.   The purpose of this follow-up study was to evaluate the efficacy of AviPhage on European poultry within a working-barn setting. AviPhage-treated birds showed lower mortality and produced higher quality meat per bird compared to the control group birds. Overall, AviPhage's broiler chickens matched or outperformed control group chickens on several key performance indicators, resulting in substanti...

Winnipeg, den 11. September 2025 - Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G) gab heute bekannt, dass zwei Patienten als Kandidaten ausgewählt wurden, die für die......

WINNIPEG, September 11, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that two patients have been selected as candidates eligible to receive Cytophage's proprietary new bacteriophage (phage) product targeting Staphylococcus aureus, a common cause of chronic prosthetic joint infection (PJI). This marks another critical milestone in the Company's ongoing efforts to advance phage-based solutions for treatment-resistant infections in humans.    Cytophage is leveraging its unique technology and extensive infectious diseases experience to optimize a phage designed to combat Staphylococcus aureus - a key target bacterium for the Company's multi-phage PJI treatment currently in development. This builds upon Cytophage's previous clinical achievements, including the delivery of Canada's first bacteriophage therapy to a patient with a PJI in 2024, and demonstrates the Company's ongoing success in creating innovative therapies ...

-          Cytophage erhält von Health Canada Unbedenklichkeitsbescheinigungen für zwei seiner innovativen Bakteriophagenprodukte -          Regulatorischer Meilenstein beschleunigt Cytophages Weg......

  Cytophage receives Letters of No Objection (LONO) from Health Canada for two of its cutting-edge bacteriophage products  Regulatory milestone accelerates Cytophage's path to commercialization and broader market access  Canada aligns with the EU and US in accepting phage technology, advancing antibiotic-free food solutions  WINNIPEG – TheNewswire - August 25, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced that it is in receipt of two Letters of No Objection (“LONO”) from Health Canada regarding its OvaPhage egg surface product and its PhageFend food surface product, marking a major regulatory milestone that will help pave the way for the introduction of innovative, science-driven solutions to enhance food safety in the Canadian market. The LONO validations affirm the safety and efficacy of bacteriophage technology for use in food processing, with OvaPhage now in the final stages of development and advancing towards commerc...

WINNIPEG – TheNewswire - August 1, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced the recent appointment of Mr. Thomas Wellner as the new Chairman of the Board subsequent to his election as a director at the Annual and Special Meeting of the Shareholders (“ASM”) on June 25, 2025. Mr. Wellner was selected by the board to stand for election and was appointed as board chairman based on his outstanding leadership experience in biotechnology and pharmaceutical companies, in-depth governance experience, and extensive global business network.  “I am honoured to be joining Cytophage's Board of Directors and grateful for the opportunity to serve as Board Chair at such a pivotal stage of the Company's product advancements,” said Mr. Wellner. “I am excited to work alongside my fellow board members and to leverage my experience to help Cytophage progress with making their cutting-edge phage technology a mainstream commercial solution f...

Folgestudie läuft - Ergebnisse werden für das dritte Quartal erwartet Winnipeg, den 28. Juli 2025 - Cytophage Technologies (Cytophage oder das Unternehmen) (TSXV:CYTO / FWB:70G) gab heute......

   Follow-up Study Underway with Results Expected in Q3/2025   WINNIPEG – TheNewswire - July 28, 2025 - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) today announced promising results of the European pilot study of AviPhage, its bacteriophage-based poultry health product, in broiler chickens (see press release April 30, 2025).   The purpose of this pilot study was to generate data on the efficacy of AviPhage on European poultry and evaluate the study protocol in a working barn setting. The study compared the AviPhage-Treated Study Group to the Control Group that received preventative standard antibiotics in respect to lowering E. coli bacteria levels. Overall, the study results show that AviPhage was comparable to or outperformed antibiotics in key performance indicators.   AviPhage is a bacteriophage-based poultry solution that has been developed by Cytophage to promote gut health, increase bird weight, improve feed conversion ratio, decrease signs of di...

WINNIPEG, June 10, 2025 — TheNewswire - Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) is pleased to announce that it has closed its previously announced non-brokered and upsized private placement (see press releases May 14, 2025 and May 29, 2025). The Company raised gross proceeds of C$1.55 million through the issuance of 7,750,000 units (each, a “Unit”) at a price of C$0.20 per Unit  (the “Offering”). Each Unit consists of one common share of the Company and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of C$0.40 per share, for a period of 24 months from the date of issuance. Cytophage may accelerate the expiry of the Warrants if the volume weighted average trading price of its Common Shares on the TSX Venture Exchange (the “Exchange”) equals or exceed $0.60 for a period of 10 consecutive trading days (the “Acceleration Right”). ...